Zhao B, et al. - Researchers investigated the prognostic values of various clinicopathological traits in patients treated with immune checkpoint inhibitors (ICIs) for metastatic melanoma. Data were analyzed from random controlled trials that compared ICIs with controls identified from PubMed, Embase and Cochrane database when searched from inception to April 2018. They pulled hazard ratios for overall survival (OS) according to gender, age, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase level and metastasis stage. Findings demonstrated ICIs were connected to prolonged OS vs conventional agents. Significantly prolonged OS in patients with metastatic melanoma treated by immunotherapy, however, only marginal long-term benefits were seen in women, younger patients (<65 years old) and patients with ECOG PS = 0. There was a significant difference in effectiveness seen between men and women.